- Bio Blast Pharma (ORPN) Q2 results: Revenues: $0; R&D Expense: $1.9M (-9.5%); SG&A: $1.7M (+6.2%); Net Loss: ($3.7M) (unch); Loss Per Share: ($0.22) (+15.4%); Quick Assets: $15.7M (-18.7%); CF Ops: ($5.7M) (-96.6%).
- No guidance given.
Bio Blast Pharma reports Q2 results
Recommended For You
About ENLV Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| ENLV | - | - |
| Enlivex Therapeutics Ltd. | ||